Please select the option that best describes you:

In a patient with multiple myeloma who cannot tolerate lenalidomide or bortezomib due to GI toxicity, what regimen would you choose for next-line therapy?  

Is there evidence for daratumumab-based doublet regimens?

Would your choice differ based on the patient's transplant eligibility?



Answer from: Medical Oncologist at Academic Institution
Sign in or Register to read more